{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:36:50Z","timestamp":1794087410068,"version":"4.8.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"37","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100023098","name":"CRT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiovascular (CV) diseases continue to cause substantial morbidity and mortality. Risk factors are inadequately controlled, compliance with medication remains suboptimal, and treatments are not sufficient to fully prevent the progression of atherosclerotic CV disease, heart failure, arrhythmias, and valvular heart diseases. An increased understanding of the genetic basis of CV diseases and advances in the technology of therapeutics have led to the development of nucleic acid\u2013based therapies (NATs) for prevention and treatment of CV risk factors and diseases. Nucleic acid\u2013based therapies can target disease pathways at the translational level preventing the formation of disease-causing proteins that could not be effectively targeted by other pharmacological therapeutics and will likely improve treatment adherence by providing long-acting effects over many months rather than daily treatment. These therapies include RNA-targeted therapeutics, gene editing therapeutics, and gene therapies. Challenges around the use of NATs may be unique with each new drug and new target and may include long-term unanticipated side effects, and issues around specificity, targeting, and stability. Assessing NATs for marketing approval continues to pose challenges for regulatory agencies. These include their diverse nature, limited data on pharmacology, clinical safety and efficacy, and the lack of long-term results. Barriers in clinical practice may include the lack of specific education, fear of off target effects, costs, and ethical challenges. Implementation of these novel therapies will require careful patient selection and education. Despite potentially high treatment costs, possible long-term cost savings could result from fewer healthcare visits due to infrequent NAT administrations, and lower rates of disease progression, hospitalization, and CV events due to sustained improvement in control of disease pathways and risk factors.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaf520","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:13:18Z","timestamp":1752502398000},"page":"5234-5246","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-3203","authenticated-orcid":false,"given":"Ulf","family":"Landmesser","sequence":"first","affiliation":[{"name":"Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum Charit\u00e9 (DHZC) , Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin ,","place":["Germany"]},{"name":"Friede Springer Cardiovascular Prevention Center@Charit\u00e9 , Hindenburgdamm 30, House IIIA, 12203 Berlin ,","place":["Germany"]},{"name":"German Center of Cardiovascular Research (DZHK) , Partner Site Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-1511","authenticated-orcid":false,"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[{"name":"Institute for Molecular and Translational Therapeutic Strategies, Medizinische Hochschule , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hacettepe University, Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5355-5910","authenticated-orcid":false,"given":"Tomasz J","family":"Guzik","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Science, University of Edinburgh , Edinburgh ,","place":["UK"]},{"name":"Department of Internal Medicine, Jagiellonian University , Collegium Medicum, Krakow ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6967-5685","authenticated-orcid":false,"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[{"name":"Unit of Cardiology, Department of Medicine Solna, Karolinksa Institutet , Stockholm ,","place":["Sweden"]},{"name":"Heart and Vascular and Neuro Theme, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hajjar","sequence":"additional","affiliation":[{"name":"Gene and Cell Therapy Institute at Mass General Brigham , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Goncalves","sequence":"additional","affiliation":[{"name":"Digital Health, Bristol, Myers & Squibb , Cambridge, MA ,","place":["USA"]},{"name":"University of Porto Medical School , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Laguna-Fernandez","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Cardiovascular, Renal and Metabolism, Novartis , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nioi","sequence":"additional","affiliation":[{"name":"Research, Alnylam Pharmaceuticals , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen H","family":"Prochaska","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim am Rhein ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rocha","sequence":"additional","affiliation":[{"name":"Medical Affairs, Intellia Therapeutics , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-7101","authenticated-orcid":false,"given":"Sekar","family":"Kathiresan","sequence":"additional","affiliation":[{"name":"Verve Therapeutics , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"M\u00e4rz","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Ethics and History of Medicine & University Research Priority Program (URPP) Innovative Therapies in Rare Diseases (ITINERARE), University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S","family":"Maurer","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2667-8624","authenticated-orcid":false,"given":"Christopher J","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Cardiovascular and Metabolism Translational Medicine, Novartis BioMedical Research , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Passacquale","sequence":"additional","affiliation":[{"name":"Innovation and Pharmaceutical Strategy Division, Agenzia Italiana del Farmaco (AIFA) , Rome ,","place":["Italy"]},{"name":"Member of the EMA Scientific Advice Working Party and Cardiovascular Working Party"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tavridou","sequence":"additional","affiliation":[{"name":"Scientific Advice Office, European Medicines Agency , Amsterdam-Zuid, North Holland ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5758-0366","authenticated-orcid":false,"given":"Mattias","family":"Van Heetvelde","sequence":"additional","affiliation":[{"name":"European Society of Cardiology Patient Forum (Belgium) , Sophia Antipolis ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Himmelmann","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Research and Development, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0741-2633","authenticated-orcid":false,"given":"Benjamin","family":"Meder","sequence":"additional","affiliation":[{"name":"Precision Digital Health & Informatics for Life, Clinic of Internal Medicine III, University of Heidelberg , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Roessig","sequence":"additional","affiliation":[{"name":"Asklepios BioPharmaceutical, Inc. (AskBio) , Research Triangle Park, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[{"name":"Centre of Excellence of Cardiovascular Sciences, Gemelli Isola Hospital , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-538X","authenticated-orcid":false,"given":"Thomas F","family":"L\u00fcscher","sequence":"additional","affiliation":[{"name":"Royal Brompton and Harefield Hospitals, Imperial College London and King\u2019s College London , London ,","place":["UK"]},{"name":"Center for Molecular Cardiology, University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"2026100419571169900_ehaf520-B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/bmj.290.6461.7","article-title":"William withering and digitalis, 1785 to 1985","volume":"290","author":"Wilkins","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2026100419571169900_ehaf520-B2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/1995-705X.95070","article-title":"Statins: past and present","volume":"12","author":"Hajar","year":"2011","journal-title":"Heart Views"},{"key":"2026100419571169900_ehaf520-B3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41588-022-01233-6","article-title":"Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants","volume":"54","author":"Aragam","year":"2022","journal-title":"Nat Genet"},{"key":"2026100419571169900_ehaf520-B4","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/eurheartj\/ehy299","article-title":"HDL-cholesterol, genetics, and coronary artery disease: the myth of the \u2018good cholesterol'?","volume":"39","author":"Landmesser","year":"2018","journal-title":"Eur Heart J"},{"key":"2026100419571169900_ehaf520-B5","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1093\/eurheartj\/ehaa229","article-title":"From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases","volume":"41","author":"Landmesser","year":"2020","journal-title":"Eur Heart J"},{"key":"2026100419571169900_ehaf520-B6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ehjcvp\/pvad034","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022","volume":"9","author":"Tamargo","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026100419571169900_ehaf520-B7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ehjcvp\/pvae013","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023","volume":"10","author":"Tamargo","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026100419571169900_ehaf520-B8","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1093\/eurheartj\/ehae466","article-title":"European society of cardiology: the 2023 atlas of cardiovascular disease statistics","volume":"45","author":"Timmis","year":"2024","journal-title":"Eur Heart J"},{"key":"2026100419571169900_ehaf520-B9","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1093\/eurheartj\/ehad583","article-title":"Economic burden of cardiovascular diseases in the European union: a population-based cost study","volume":"44","author":"Luengo-Fernandez","year":"2023","journal-title":"Eur Heart J"},{"key":"2026100419571169900_ehaf520-B10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIR.0000000000000981","article-title":"A call to action for new global approaches to cardiovascular disease drug solutions","volume":"144","author":"Figtree","year":"2021","journal-title":"Circulation"},{"key":"2026100419571169900_ehaf520-B11","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026100419571169900_ehaf520-B12","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1093\/eurheartj\/ehae558","article-title":"Variation in secondary prevention of coronary heart disease: the INTERASPIRE study","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026100419571169900_ehaf520-B13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ehjcvp\/pvac005","article-title":"Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"8","author":"Tamargo","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026100419571169900_ehaf520-B14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pcad.2023.08.001","article-title":"Unmet needs and future directions in hypertrophic cardiomyopathy","volume":"80","author":"Kaur","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"2026100419571169900_ehaf520-B16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2023","journal-title":"Nat Med"},{"key":"2026100419571169900_ehaf520-B17","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra0902923","article-title":"Inherited cardiomyopathies","volume":"364","author":"Watkins","year":"2011","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41431-024-01660-5","article-title":"Genetic therapies for cardiomyopathy: survey of attitudes of the patient community for the CureHeart project","volume":"32","author":"Ormondroyd","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"2026100419571169900_ehaf520-B19","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/eurjpc\/zwaa156","article-title":"Current perceptions and practices in lipid management: results of a European Society of Cardiology\/European Atherosclerosis Society Survey","volume":"28","author":"Koskinas","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026100419571169900_ehaf520-B20","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026100419571169900_ehaf520-B21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/imj.13736","article-title":"Improving patient adherence to secondary prevention medications 6 months after an acute coronary syndrome: observational cohort study","volume":"48","author":"Brieger","year":"2018","journal-title":"Intern Med J"},{"key":"2026100419571169900_ehaf520-B22","doi-asserted-by":"publisher","first-page":"e011765","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026100419571169900_ehaf520-B23","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur Heart J"},{"key":"2026100419571169900_ehaf520-B24","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.1021\/acs.jmedchem.2c00024","article-title":"The progress and promise of RNA medicine\u2014an arsenal of targeted treatments","volume":"65","author":"Sasso","year":"2022","journal-title":"J Med Chem"},{"key":"2026100419571169900_ehaf520-B25","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"2026100419571169900_ehaf520-B26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.hrtlng.2021.03.065","article-title":"P010. Evaluation of the efficacy and safety of AKCEA-TTR-LRx (ION-682884) in patients with transthyretin-mediated amyloid cardiomyopathy: the CARDIO-TTRansform study","volume":"50","author":"Maurer","year":"2021","journal-title":"Heart Lung"},{"key":"2026100419571169900_ehaf520-B27","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026100419571169900_ehaf520-B28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/ph16040577","article-title":"Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a)","volume":"16","author":"Katsiki","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026100419571169900_ehaf520-B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"2026100419571169900_ehaf520-B34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B35","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial","volume":"331","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"2026100419571169900_ehaf520-B36","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"2026100419571169900_ehaf520-B37","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B38","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ejhf.3139","article-title":"Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: rationale and design of the HF-REVERT trial","volume":"26","author":"Bauersachs","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026100419571169900_ehaf520-B39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","article-title":"Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device\u2014the SERCA-LVAD TRIAL","volume":"27","author":"Lyon","year":"2020","journal-title":"Gene Ther"},{"key":"2026100419571169900_ehaf520-B40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","article-title":"VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients","volume":"10","author":"Horie","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026100419571169900_ehaf520-B41","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0735-1097(24)03663-5","article-title":"Solbinsiran, a GalNAc-conjugated sirna targeting ANGPTL3, reduces atherogenic lipoproteins in individuals with mixed dyslipidaemia in a durable and dosedependent manner","volume":"83","author":"Ray","year":"2024","journal-title":"JACC"},{"key":"2026100419571169900_ehaf520-B42","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11883-023-01156-5","article-title":"Updates in small interfering RNA for the treatment of dyslipidemias","volume":"25","author":"Carugo","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"2026100419571169900_ehaf520-B43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering siRNA therapeutics: challenges and strategies","volume":"21","author":"Ali Zaidi","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"2026100419571169900_ehaf520-B44","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med"},{"key":"2026100419571169900_ehaf520-B45","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B46","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis.","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026100419571169900_ehaf520-B47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B48","doi-asserted-by":"publisher","first-page":"628137","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"2026100419571169900_ehaf520-B49","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.123.067957","article-title":"Established and emerging nucleic acid therapies for familial hypercholesterolemia","volume":"150","author":"Damase","year":"2024","journal-title":"Circulation"},{"key":"2026100419571169900_ehaf520-B50","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/s41591-024-03273-3","article-title":"How to make cardiology clinical trials more inclusive","volume":"30","author":"Zannad","year":"2024","journal-title":"Nat Med"},{"key":"2026100419571169900_ehaf520-B51","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/hum.2015.025","article-title":"Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success\u2013a personal perspective","volume":"26","author":"Hastie","year":"2015","journal-title":"Hum Gene Ther"},{"key":"2026100419571169900_ehaf520-B52","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCRESAHA.118.311587","article-title":"Human cardiac gene therapy","volume":"123","author":"Ishikawa","year":"2018","journal-title":"Circ Res"},{"key":"2026100419571169900_ehaf520-B53","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"2026100419571169900_ehaf520-B54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nbt.1599","article-title":"Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle","volume":"28","author":"Asokan","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2026100419571169900_ehaf520-B55","first-page":"3","article-title":"A phase 1 clinical trial of high dose AAV1.SERCA2a in patients with heart failure: modulation of SERCA2a of intra- myocytic calcium trafficking in heart failure with reduced ejection fraction (MUSIC-HFrEF) [abstract]","volume":"31","author":"Jaski","year":"2024","journal-title":"Mol Ther"},{"key":"2026100419571169900_ehaf520-B56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ymthe.2021.12.007","article-title":"A first-in-human phase 1 clinical gene therapy trial for the treatment of heart failure using a novel re-engineered adeno- associated vector molecular therapy [abstract]","volume":"30","author":"Henry","year":"2022","journal-title":"Mol Ther"},{"key":"2026100419571169900_ehaf520-B57","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease","volume":"392","author":"Greenberg","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100419571169900_ehaf520-B58","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1093\/cvr\/cvae107","article-title":"The promise of gene therapy in hypertrophic cardiomyopathy: emergence of human experience","volume":"120","author":"Desai","year":"2024","journal-title":"Cardiovascular Research"},{"key":"2026100419571169900_ehaf520-B59","doi-asserted-by":"publisher","first-page":"e18761429264553","DOI":"10.2174\/0118761429264553231204115314","article-title":"RNA interference-based therapies for the reduction of cardiovascular risk","volume":"17","author":"Nazarenko","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"2026100419571169900_ehaf520-B60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11427-022-2171-2","article-title":"RNA therapeutics: updates and future potential","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci China Life Sci"},{"key":"2026100419571169900_ehaf520-B61","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3390\/biom13101497","article-title":"Enabling mRNA therapeutics: current landscape and challenges in manufacturing","volume":"13","author":"Youssef","year":"2023","journal-title":"Biomolecules"},{"key":"2026100419571169900_ehaf520-B62","author":"European Medicines Agency"},{"key":"2026100419571169900_ehaf520-B63","author":"European Medicines Agency"},{"key":"2026100419571169900_ehaf520-B64"},{"key":"2026100419571169900_ehaf520-B65","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1111\/bcp.14672","article-title":"Towards a better use of scientific advice for developers of advanced therapies","volume":"87","author":"Tavridou","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026100419571169900_ehaf520-B66","author":"European Medicines Agency"},{"key":"2026100419571169900_ehaf520-B67","author":"European Commission"},{"key":"2026100419571169900_ehaf520-B68","author":"U.S. Food and Drug Administration"},{"key":"2026100419571169900_ehaf520-B69","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/clc.22963","article-title":"Treatment in a preventive cardiology clinic utilizing advanced practice providers effectively closes atherosclerotic cardiovascular disease risk-management gaps among a primary-prevention population compared with a propensity-matched primary-care cohort: a team-based care model and its impact on lipid and blood pressure management","volume":"41","author":"Fentanes","year":"2018","journal-title":"Clin Cardiol"},{"key":"2026100419571169900_ehaf520-B70","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1093\/eurheartj\/ehu364","article-title":"Non-adherence to cardiovascular medications","volume":"35","author":"Kolandaivelu","year":"2014","journal-title":"Eur Heart J"},{"key":"2026100419571169900_ehaf520-B71","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1093\/eurheartj\/ehab310","article-title":"Redefining cardiovascular risk prediction: is the crystal ball clearer now?","volume":"42","author":"Tokgozoglu","year":"2021","journal-title":"Eur Heart J"},{"key":"2026100419571169900_ehaf520-B72","author":"Verve Therapeutics"},{"key":"2026100419571169900_ehaf520-B73","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/clc.23988","article-title":"Addressing current challenges in optimization of lipid management following an ACS event: outcomes of the ACS EuroPath III initiative","volume":"46","author":"Catapano","year":"2023","journal-title":"Clin Cardiol"},{"key":"2026100419571169900_ehaf520-B74","doi-asserted-by":"publisher","first-page":"156","DOI":"10.18203\/2349-3259.ijct20231106","article-title":"Implementation of inclisiran in UK primary care for patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents: rationale and design of VICTORION-spirit, a pragmatic phase IIIb, randomised controlled study","volume":"10","author":"Wilson","year":"2023","journal-title":"Int J Clin Trials"},{"key":"2026100419571169900_ehaf520-B75","author":"IQWiG Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen"},{"key":"2026100419571169900_ehaf520-B76","author":"World Medical Association"},{"key":"2026100419571169900_ehaf520-B77","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.21.0146","article-title":"Building a value-based care infrastructure in Europe: the health outcomes observatory","volume":"2","author":"Stamm","year":"2021","journal-title":"NEJM Catal Innov Care Deliv"},{"key":"2026100419571169900_ehaf520-B78","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1161\/CIR.0000000000001143","article-title":"Value-based payment for clinicians treating cardiovascular disease: a policy statement from the American Heart Association","volume":"148","author":"Sandhu","year":"2023","journal-title":"Circulation"},{"key":"2026100419571169900_ehaf520-B79","doi-asserted-by":"publisher","first-page":"e47731","DOI":"10.7759\/cureus.47731","article-title":"Improving patient outcomes through effective hospital administration: a comprehensive review","volume":"15","author":"Bhati","year":"2023","journal-title":"Cureus"},{"key":"2026100419571169900_ehaf520-B80","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jval.2021.11.1355","article-title":"The roadmap for implementing value-based healthcare in European university hospitals-consensus report and recommendations","volume":"25","author":"Cossio-Gil","year":"2022","journal-title":"Value Health"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/37\/5234\/64103419\/ehaf520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/37\/5234\/64103419\/ehaf520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:57:17Z","timestamp":1791158237000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/37\/5234\/8239270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":80,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2025,8,21]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf520","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,1]]},"published":{"date-parts":[[2025,8,21]]}}}